Prognostic Value of Hsa-mir-299 and Hsa-mir-7706 in Hepatocellular Carcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jul 3

PMID 29963149

Citations 9

Authors

Fenglin Wang

Min Dai

Hongjie Chen

Yue Li

Jiongshan Zhang

Zengcheng Zou

Hongzhi Yang

Affiliations

Soon will be listed here.

Abstract

This study aimed to investigate the expression of microRNA (miRNA) 299 and miRNA-7706 in patients with hepatocellular carcinoma (HCC), and to explore their effects on proliferation of SK-HEP-1 HCC cells. Expression of miRNA-299 and miRNA-7706 in tumor tissue (HCC group) and adjacent healthy tissue (>30 mm away from the tumor tissue) of 179 patients with HCC was determined by real-time polymerase chain reaction (qRT-PCR). miR-299 mimics and miR-7706 mimics were transfected into SK-HEP-1 HCC cells by RNA transfection. The proliferation and invasion of SK-HEP-1 cells were detected by CCK-8 kit and Transwell kit, respectively. Compared with adjacent tissues, expression levels of miRNA-299 and miRNA-7706 in HCC group were significantly downregulated. Analyses on the correlation between the expression of miRNA-299 and miRNA-7706 and clinical factors showed that expression levels of miRNA-299 and miRNA-7706 were significantly correlated with pathological stages and lymph node metastasis. ROC curve analysis showed that the areas under the curve were 0.837 and 0.845 for miRNA-299 and miRNA-7706 in the prediction of HCC, respectively. Survival analysis showed that the 5-year overall survival rate of patients with high expression levels of miRNA-299 and miRNA-7706 was significantly different from that of patients with low expression levels (P=0.016). Compared with cells transfected with scramble mimics, proliferation and invasion abilities of SK-HEP-1 cells transfected with miR-299 mimics and miRNA-7706 were significantly weakened. Results suggested that downregulation of miRNA-299 and miRNA-7706 can inhibit the proliferation of HCC cells and can be used as a new target for the treatment of HCC.

Citing Articles

miR-19a-3p promotes the growth of hepatocellular carcinoma by regulating p53/SOX4.

Zhang H, Zhu J, Zhang J, Liu Y, Zhao B, Yang X Heliyon. 2024; 10(16):e36282.

PMID: 39253193 PMC: 11381758. DOI: 10.1016/j.heliyon.2024.e36282.

Characteristics of MicroRNA Expression Depending on the Presence or Absence of Meningioma in Patients with Neurofibromatosis Type 2: A Secondary Analysis.

Imura T, Mitsuhara T, Horie N Neurol Med Chir (Tokyo). 2024; 64(3):116-122.

PMID: 38267057 PMC: 10992986. DOI: 10.2176/jns-nmc.2023-0200.

The investigation of circRNA profiling reveals the regulatory role of the hsa_circ_0000375/miR-7706 pathway in breast cancer.

Wang H, Liu F, Xue J, Liu Y, Gao W, Yang S Mol Biol Rep. 2023; 50(12):9993-10004.

PMID: 37904009 DOI: 10.1007/s11033-023-08798-3.

Decreased microRNA-768-3p expression indicates a poor prognosis in patients with breast cancer and promotes breast cancer cell viability, migration and invasion.

Zhou Y, Wang Y, Wang L, Zhang J, Liu X Oncol Lett. 2021; 22(2):579.

PMID: 34122630 PMC: 8190777. DOI: 10.3892/ol.2021.12840.

Comprehensive Analysis of Correlations in the Expression of miRNA Genes and Immune Checkpoint Genes in Bladder Cancer Cells.

Stempor P, Avni D, Leibowitz R, Sidi Y, Stepien M, Dzieciatkowski T Int J Mol Sci. 2021; 22(5).

PMID: 33806327 PMC: 7961343. DOI: 10.3390/ijms22052553.

References

Reddy K . MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015; 15:38. PMC: 4424445. DOI: 10.1186/s12935-015-0185-1. View

Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y . JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2015; 3(3-4):458-68. PMC: 4531423. DOI: 10.1159/000343875. View

Fateh A, Feizi M, Safaralizadeh R, Azarbarzin S . Importance of miR-299-5p in colorectal cancer. Ann Gastroenterol. 2017; 30(3):322-326. PMC: 5411383. DOI: 10.20524/aog.2017.0139. View

Zhang Y, Xu Z, Zhang T, Wang Y . Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma. World J Gastroenterol. 2015; 21(34):9853-62. PMC: 4566380. DOI: 10.3748/wjg.v21.i34.9853. View

Ren S, Xin Z, Xu Y, Xu J, Wang G . Construction and analysis of circular RNA molecular regulatory networks in liver cancer. Cell Cycle. 2017; 16(22):2204-2211. PMC: 5736333. DOI: 10.1080/15384101.2017.1346754. View

Gohring A, Reuter S, Clement J, Cheng X, Theobald J, Wolfl S . Human microRNA-299-3p decreases invasive behavior of cancer cells by downregulation of Oct4 expression and causes apoptosis. PLoS One. 2017; 12(4):e0174912. PMC: 5398498. DOI: 10.1371/journal.pone.0174912. View

Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du Y . miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer. 2012; 12:111. PMC: 3350382. DOI: 10.1186/1471-2407-12-111. View

Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T . Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 2015; 45(2). DOI: 10.1111/hepr.12464. View

Shenoy A, Blelloch R . Regulation of microRNA function in somatic stem cell proliferation and differentiation. Nat Rev Mol Cell Biol. 2014; 15(9):565-76. PMC: 4377327. DOI: 10.1038/nrm3854. View

10.

Liu L, Chen X, Zhang Y, Hu Y, Shen X, Zhu W . Long non-coding RNA TUG1 promotes endometrial cancer development via inhibiting miR-299 and miR-34a-5p. Oncotarget. 2017; 8(19):31386-31394. PMC: 5458215. DOI: 10.18632/oncotarget.15607. View

11.

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

12.

Hsu S, Tseng Y, Shrestha S, Lin Y, Khaleel A, Chou C . miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 2013; 42(Database issue):D78-85. PMC: 3965058. DOI: 10.1093/nar/gkt1266. View

13.

Kim H, Lee K, Bae H, Eun J, Shen Q, Park S . MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget. 2015; 6(10):8089-102. PMC: 4480737. DOI: 10.18632/oncotarget.3512. View

14.

Xing Y, Cui D, Wang S, Wang P, Xing X, Li H . Oleuropein represses the radiation resistance of ovarian cancer by inhibiting hypoxia and microRNA-299-targetted heparanase expression. Food Funct. 2017; 8(8):2857-2864. DOI: 10.1039/c7fo00552k. View

15.

Yoshimoto S, Loo T, Atarashi K, Kanda H, Sato S, Oyadomari S . Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013; 499(7456):97-101. DOI: 10.1038/nature12347. View

16.

Mittal S, El-Serag H . Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013; 47 Suppl:S2-6. PMC: 3683119. DOI: 10.1097/MCG.0b013e3182872f29. View

17.

Yuan Q, Loya K, Rani B, Mobus S, Balakrishnan A, Lamle J . MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology. 2012; 57(1):299-310. DOI: 10.1002/hep.25984. View

18.

Tang H, Li R, Liang P, Zhou Y, Wang G . miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol Lett. 2015; 10(2):681-686. PMC: 4509408. DOI: 10.3892/ol.2015.3264. View

19.

Lee Y, Kim V, Muth D, Witwer K . Validated MicroRNA Target Databases: An Evaluation. Drug Dev Res. 2015; 76(7):389-96. PMC: 4777876. DOI: 10.1002/ddr.21278. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View